Search

Learn about MSK’s active surveillance program for papillary thyroid cancer, which allows many people to avoid unnecessary surgery and the risks that come with it.

… Wednesday, November 13, 2024 Advances in cancer detection have saved many lives, but they have a serious drawback: Some cancers are being overdiagnosed, which can lead to the unnecessary treatment of tumors that would have posed no threat if left alone.  One cancer that may not need treatment right away

Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD, a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment, which is effective immediately, Dr. Cahlon will help oversee the network’s outpatient clinical programs, which span seven locations across New York and New Jersey.

… Friday, November 23, 2018 Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD , a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment

Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not harbor the BRAF V600 mutation. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma. This designation was granted based on data submitted by MSK, in collaboration with Genentech, a member of the Roche Group, from a phase II trial of single-agent cobimetinib for adults with histiocytic disorders (published in Nature in March 2019 by Eli Diamond, MD; Omar Abdel-Wahab, MD; and David Hyman, MD).

… Wednesday, October 2, 2019 Bottom Line: Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman

MSK President and CEO, Craig B. Thompson, MD, has been named a founding member of the New York Jobs CEO Council. Dr. Thompson joins CEOs from 27 of the largest employers in New York in the new CEO-led, action-oriented coalition.

… Tuesday, August 11, 2020 Memorial Sloan Kettering President and CEO, Craig B. Thompson, MD , has been named a founding member of the New York Jobs CEO Council. Dr. Thompson joins CEOs from 27 of the largest employers in New York in the new CEO-led, action-oriented coalition. The council will collaborate

Scientists are dusting off their biochemistry textbooks in the hunt for clues to cancer.

… Wednesday, November 23, 2016 Summary Prompted by MSK President and CEO Craig Thompson , cancer researchers are returning to the topic of metabolism for answers about what makes cancer cells go haywire. Highlights Metabolism refers to how cells acquire nutrients and energy. The products of metabolism

In the past 30 years, major strides have been made in translational medicine — the bridge that shepherds research findings from the lab to clinical practice. Researchers, physicians, and other specialists at Memorial Sloan Kettering Cancer Center (MSK) have played a major role in these successes, as they work together with the common goal of using their discoveries to create new treatments for people with cancer.

… Friday, August 12, 2022 In the past 30 years, major strides have been made in translational medicine — the bridge that shepherds research findings from the lab to clinical practice. Researchers, physicians, and other specialists at Memorial Sloan Kettering Cancer Center (MSK) have played a major role

The list honors health care leaders who envision a better future for all New Yorkers.

… Wednesday, December 1, 2021 Craig B. Thompson, MD , President and CEO of Memorial Sloan Kettering Cancer Center (MSK), has been named to the first AMNY Metro and PoliticsNY ’s Power Players in Health Care list. The list salutes top public officials, policymakers, hospital and health maintenance organization

Sometimes a BRCA mutation is just along for the ride, rather than driving a tumor’s development.

… Wednesday, July 10, 2019 VIDEO | 00:54 Watch: Not All BRCA Mutations Cause Patients' Cancer, Study Finds Computational biologist Barry Taylor discusses findings of a new study about BRCA genes. Video Details Summary Scientists at Memorial Sloan Kettering have discovered that BRCA1 and BRCA2 mutations

A team of doctors and researchers at MSK have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked. Learn how one 19-year-old patient sparked a detective story.

… Wednesday, September 11, 2024 A team of doctors and researchers at Memorial Sloan Kettering Cancer Center (MSK) have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked. Their findings, which include a detailed analysis of the clinical and

Un equipo de médicos e investigadores de MSK ha identificado un nuevo y raro tipo de cáncer pulmonar de células pequeñas que afecta principalmente a personas jóvenes que nunca han fumado. Descubra cómo un paciente de 19 años inspiró una historia de investigación.

… Wednesday, September 11, 2024 Un equipo de médicos e investigadores del Memorial Sloan Kettering Cancer Center (MSK) ha identificado un nuevo y raro tipo de cáncer pulmonar de células pequeñas que afecta principalmente a personas jóvenes que nunca han fumado. Sus hallazgos, que incluyen un análisis detallado